Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Aprocitentan Tablets in the Treatment of Resistant Hypertension

NCT07635914 is registered in ClinicalTrials.gov with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. as lead sponsor.

NCT NCT07635914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07635914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Aprocitentan Tablets in the Treatment of Resistant Hypertension
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2030
Enrollment
382 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

resistant hypertension